Study identifies women with breast cancer most likely to benefit from aromatase inhibitor

	Tweet

While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Writing in the December 1, 2006 issue of CANCER (http://www.interscience.wiley.com/cancer-newsroom), a peer-reviewed journal of the American Cancer Society, the study’s authors say potential improvement in cancer-free survival beyond 5 years with the added therapy may be less than 2 percent for most patients.

For decades, clinicians have given breast cancer patients tamoxifen, which has been shown to improve survival when given for five years. More recently, aromatase inhibitors, another class of estrogen modulating drugs, have been used to prevent estrogen formation. A large randomized study has shown that use of aromatase inhibitors after tamoxifen may further improve survival and is recommended for postmenopausal women. Led by Gary M. Freedman, M.D. of the Fox Chase Cancer Center in Philadelphia, researchers investigated which sub-groups of breast cancer patients treated with tamoxifen may benefit the most from this extended therapy with aromatase inhibitors.

The researchers found that in this study population of 471 women, the potential addition of an aromatase inhibitor would have provided only marginal benefits. Premenopausal women and patients with at least four positive lymph nodes would experience the greatest 10-year cancer-free survival benefits. Patients with none or fewer positive lymph nodes, advanced age, or other medical problems that would limit their life expectancy would not have the same benefit from 5 more years of therapy.

“Based upon our findings,” the authors conclude, “women who are premenopausal at the time of initial therapy and patients who have 4 or more positive lymph nodes will have the greatest potential benefit from the addition of extended adjuvant anti-estrogen therapy.” For patients over 60 years old, “the decision needs to be individualized based upon their initial nodal status and presence of comorbidities that would reduce their 5-year life expectancy.”

RELATED STORIES:
New Test Discovered to Better Predict Breast Cancer Outcomes   Biophysicist targeting IL-6 to halt breast, prostate cancer   Newer breast cancer drug seen safer than tamoxifen   Novel methods for improved breast cancer survival   ‘Prudent’ diet linked to lower breast cancer risk   Breast MRI spots other cancers, may alter treatment plan   Screening mammograms catch second breast cancers early   Oral contraceptive use associated with increased risk of breast cancer   New leaflet offers breast cancer help   Breast Cancer Risk Found High After Chest Radiation for Hodgkin’s   Clues to Pregnancy-Associated Breast Cancer Found   Marijuana Compound Shows Promise in Fighting Breast Cancer   New Tool to Diagnose and Treat Breast Cancer   New Genetic Test for Personalized Treatment of Breast Cancer   High-risk women reluctant to take tamoxifen to prevent breast cancer   Why women quit breast cancer drugs early   Associations Between Pregnancy, Breastfeeding, Breast Cancer and Survival Detailed   Colour sensor breath test can detect lung cancer   Women with BRCA Mutation, Or High Degree of Worry, Most Likely to Undergo Prophylactic Mastectomy   Psychological interventions associated with breast cancer survival   Link Found Between Vegetables and Decreased Risk of Breast Cancer   Nurse Runs to Raise Funds for Family Fight Against Breast Cancer

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]